English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objectives   K aposi's sarcoma ( KS ), invasive cervical carcinoma ( ICC ) and non‐ H odgkin lymphoma ( NHL ) have been listed as  AIDS ‐defining cancers ( ADCs ) by the Centers for Disease Control and Prevention since 1993. Despite this,  HIV  screening is not universally mentioned in  ADC  treatment guidelines. We examined screening practices at a tertiary centre serving a population where  HIV  seroprevalence is 0.4%.    Methods  Patients with  KS ,  ICC ,  NHL  and  H odgkin lymphoma ( HL ), treated at  L ausanne  U niversity  H ospital between  J anuary 2002 and  J uly 2012, were studied retrospectively.  HIV  testing was considered part of the oncology work‐up if performed between 90 days before and 90 days after the cancer diagnosis date.    Results  A total of 880 patients were examined: 10 with  KS , 58 with  ICC , 672 with  NHL  and 140 with  HL .  HIV  testing rates were 100, 11, 60 and 59%, and  HIV  seroprevalence was 60, 1.7, 3.4 and 5%, respectively. Thirty‐seven patients (4.2%) were  HIV ‐positive, of whom eight (22%) were diagnosed at oncology work‐up. All newly diagnosed patients had  CD4  counts < 200 cells/μL and six (75%) had presented to a physician 12–236 weeks previously with conditions warranting  HIV  testing.    Conclusions  In our institution, only patients with  KS  were universally screened. Screening rates for other cancers ranged from 11 to 60%.  HIV  seroprevalence was at least fourfold higher than the population average. As  HIV ‐positive status impacts on cancer patient medical management,  HIV  screening should be included in oncology guidelines. Further, we recommend that opt‐out screening should be adopted in all patients with  ADCs  and  HL .

hiv medicine

Patients with  AIDS ‐defining cancers are not universally screened for  HIV : a 10‐year retrospective analysis of  HIV ‐testing practices in a  S wiss university hospital